80 related articles for article (PubMed ID: 12400609)
1. Antigen presenting cells transfected with LMP2a RNA induce CD4+ LMP2a-specific cytotoxic T lymphocytes which kill via a Fas-independent mechanism.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Leuk Lymphoma; 2002 Aug; 43(8):1651-62. PubMed ID: 12400609
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
[TBL] [Abstract][Full Text] [Related]
3. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
[TBL] [Abstract][Full Text] [Related]
4. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans.
Yasukawa M; Ohminami H; Arai J; Kasahara Y; Ishida Y; Fujita S
Blood; 2000 Apr; 95(7):2352-5. PubMed ID: 10733506
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma.
Gahn B; Siller-Lopez F; Pirooz AD; Yvon E; Gottschalk S; Longnecker R; Brenner MK; Heslop HE; Aguilar-Cordova E; Rooney CM
Int J Cancer; 2001 Sep; 93(5):706-13. PubMed ID: 11477583
[TBL] [Abstract][Full Text] [Related]
6. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.
Sohn DH; Sohn HJ; Lee HJ; Lee SD; Kim S; Hyun SJ; Cho HI; Cho SG; Lee SK; Kim TG
PLoS One; 2015; 10(5):e0127899. PubMed ID: 26023769
[TBL] [Abstract][Full Text] [Related]
7. EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.
Chen Y; Sun H; Liu G; Wang B; Wang F; Sun B; Yao K
Cell Mol Immunol; 2009 Aug; 6(4):269-76. PubMed ID: 19728928
[TBL] [Abstract][Full Text] [Related]
8. Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A).
Chen Y; Yao K; Wang B; Qing J; Liu G
Cell Mol Immunol; 2008 Oct; 5(5):365-72. PubMed ID: 18954560
[TBL] [Abstract][Full Text] [Related]
9. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells.
Yasukawa M; Ohminami H; Yakushijin Y; Arai J; Hasegawa A; Ishida Y; Fujita S
J Immunol; 1999 May; 162(10):6100-6. PubMed ID: 10229852
[TBL] [Abstract][Full Text] [Related]
10. Reconstituted complexes of mycobacterial HSP70 and EBV LMP2A-derived peptides elicit peptide-specific cytotoxic T lymphocyte responses and anti-tumor immunity.
Liu G; Yao K; Wang B; Zhou F; Chen Y; Li L; Chi J; Peng G
Vaccine; 2011 Oct; 29(43):7414-23. PubMed ID: 21807054
[TBL] [Abstract][Full Text] [Related]
11. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
12. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
Sun H; Yao K; Chen Y; Zhou F
Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
[TBL] [Abstract][Full Text] [Related]
13. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
[TBL] [Abstract][Full Text] [Related]
14. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity.
Stalder T; Hahn S; Erb P
J Immunol; 1994 Feb; 152(3):1127-33. PubMed ID: 7507960
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
16. EBV Latency II-derived peptides induce a specific CD4+ cytotoxic T-cell activity and not a CD4+ regulatory T-cell response.
Moralès O; Depil S; Mrizak D; Martin N; Ndour PA; Dufosse F; Miroux C; Coll J; de Launoit Y; Auriault C; Pancre V; Delhem N
J Immunother; 2012 Apr; 35(3):254-66. PubMed ID: 22421943
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of the therapeutic effectiveness of EBV-LMP2 recombinant adenovirus vaccine in nasopharyngeal carcinoma.
Ge Y; Zhou Z; Wang X; Zhou Y; Liu W; Teng Z; Zeng Y
Biomed Pharmacother; 2020 Jan; 121():109626. PubMed ID: 31743878
[TBL] [Abstract][Full Text] [Related]
19. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.
Lewinsohn DM; Bement TT; Xu J; Lynch DH; Grabstein KH; Reed SG; Alderson MR
J Immunol; 1998 Mar; 160(5):2374-9. PubMed ID: 9498779
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
